Trabedersen is a first-in-class gene silencing antisense compound designed to inhibit the tumour factor – transforming growth factor beta 2 (TGF-ß2) at its translational level.
The efficacy and tolerability of trabedersen for high-grade glioma was observed in a randomised and actively controlled Phase IIb study.
Trabedersen is currently in clinical development for indications such as advanced pancreas carcinoma, malignant melanoma and colorectal carcinoma.
In addition to South Korea and Taiwan, a total of 13 countries are now participating in the international pivotal study.
The randomised and actively controlled Phase III study SAPPHIRE will begin at selected medical centres in South Korea and Taiwan during the first quarter of 2011
Antisense Pharma chief medical officer Dr Hubert Heinrichs said the excellent exchange with the regulatory authorities in South Korea and Taiwan has led to a prompt granting of approvals.
"Key factors for the decision taken by KFDA and TFDA have surely been the very encouraging results of previous clinical studies which confirm the safety, tolerability and efficacy of trabedersen," Heinrichs added.